GtoPdb Ligand ID: 6882

Synonyms: C225 | Erbitux® | IMC-225 | IMC-C225
cetuximab is an approved drug (FDA (2004), EMA (2004))
Compound class: Antibody
Comment: Cetuximab binds to and competitively inhibits the activity of the epidermal growth factor receptor (EGFR).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

As Bristol-Myers Squibb's original EU and US patents for cetuximab have expired, challengers of cetuximab's market position are developing biosimilar and/or biobetter cetuximab.
Celltrion's CT-P15 is a cetuximab biosimilar, intended for the treatment of colorectal cancer. MabTech-Sorrento's STI-001 is a proposed biobetter cetuximab (perhaps because synthesis in CHO cells creates a different glycosylation pattern to that of cetuximab which is made in mouse cells, and may be less likely to cause side-effects such as immunogenicity and hypersensitivity). STI-001 has completed Phase 3 clinical trial in China. Neither of these agents is associated with any clinical studies that are registered with ClinicalTrials.gov.
Compound class Antibody
Approved drug? Yes (FDA (2004), EMA (2004))
International Nonproprietary Names
INN number INN
7906 cetuximab
C225 | Erbitux® | IMC-225 | IMC-C225
Database Links
Specialist databases
IMGT/mAb-DB 151
Other databases
GtoPdb PubChem SID 178103464
PubChem SID 178103464
Search PubMed clinical trials cetuximab
Search PubMed titles cetuximab
Search PubMed titles/abstracts cetuximab
Wikipedia Cetuximab